Rigel Pharmaceuticals (RIGL +3.2%) signs an agreement to develop its R256 asthma drug with...

|By:, SA News Editor

Rigel Pharmaceuticals (RIGL +3.2%) signs an agreement to develop its R256 asthma drug with AstraZeneca (AZN +3%) in a deal that could be worth $100M plus royalties if the treatment ever reaches market. There's still a long way to go, as R256 is yet to be tested on humans. (PR)